

“肺与大肠相表里”的黏膜免疫调节机制及中药干预作用研究进展

楼招欢,赵华军,吕圭源

浙江中医药大学药学院,浙江 杭州 310053



[摘要] “肺与大肠相表里”是中医学经典理论之一,揭示了肺与大肠在生理、病理上的密切相关性,在肺、肠疾病治疗上具有重要指导意义。现代医学已揭示肺与大肠在组织来源、黏膜免疫上的联系,初步明确了“肺与大肠相表里”的物质基础及可能的调节机制,并将此理论应用于 2019 冠状病毒病、溃疡性结肠炎等肺肠难治病的治疗,获得可靠疗效。现有研究表明,肺与大肠解剖上的同质性促使了肺-肠黏膜免疫功能的相关性,黏膜免疫及固有淋巴细胞的迁移归巢是肺与大肠共享生理病理的调节机制之一。部分清热解毒类中药和补益类中药通过调节肺-肠黏膜免疫功能治疗肺、肠疾病,成为“肺肠同治”创新药物研发的候选药物。然而,上述两类中药现有免疫调节相关研究主要集中于对分泌型 IgA、细胞因子等表达水平及固有淋巴细胞、B 淋巴细胞等免疫细胞数量的变化上,对与之相关的气道、肠道黏液高分泌、肺及肠道黏膜屏障免疫细胞功能改变、肺-肠黏膜免疫相互作用动态过程及肺-肠局部微生态的干预作用,以及清热解毒、补益功效与其调节肺-肠黏膜免疫作用间的相关性和生物学基础等尚缺乏深入研究。本文试从肺、肠共同拥有的黏膜免疫系统切入,从黏膜固有淋巴细胞归巢角度分析肺肠相关疾病的内在联系,并综述对肺、肠黏膜免疫具有调节作用的中药复方及其有效成分的作用特点和规律,为“肺与大肠相表里”理论内涵的深入阐释及相关疾病治疗药物的研发提供参考。

[关键词] 肺-肠轴;免疫;黏膜;固有淋巴细胞;淋巴细胞归巢;中医药治疗

[中图分类号] R285.5 **[文献标志码]** A

Mechanism and intervention of mucosal immune regulation based on “lung and large intestine being interior-exteriorly related” theory of traditional Chinese medicine

LOU Zhaohuan, ZHAO Huajun, LYU Guiyuan (College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China)

收稿日期:2020-08-07 接受日期:2020-10-23

基金项目:浙江省重点实验室项目(2012E10002);浙江省中医药科技计划(2019ZB034);浙江中医药大学科研基金项目(2020ZG22)

第一作者:楼招欢(1978—),女,博士,副研究员,硕士生导师,主要从事中药药理及新产品开发研究;E-mail: zhaohuanlou@zcmu.edu.cn; <https://orcid.org/0000-0002-7367-3500>

通信作者:吕圭源(1954—),男,学士,教授,博士生导师,主要从事中药药理与新产品开发研究;E-mail: lv.gy@263.net; <https://orcid.org/0000-0002-8381-2244>

Corresponding author: LYU Guiyuan, E-mail: lv.gy@263.net, <https://orcid.org/0000-0002-8381-2244>

[Abstract] The “lung and large intestine being interior-exteriorly related” is one of the classical theories in traditional Chinese medicine, which indicates a close correlation between the lung and large intestine in physiology and pathology, and plays a pivotal role in guiding the treatment of the lung and bowel diseases. Modern medicine has revealed some connections between the lung and large intestine in tissue origin and mucosal immunity, and preliminarily illuminated the material basis and possible regulatory mechanism of the theory. Recently, this theory has been applied to guide the treatment of refractory lung and intestine diseases such as COVID-19 and ulcerative colitis and has obtained reliable efficacy. Existing research results show that the anatomical homogeneity of lung and large intestine promotes the correlation between lung-bowel mucosal immunity, and mucosal immunity and migration and homing of innate lymphocytes are one of the physiological and pathological mechanisms for lung and large intestine to share. Under the guidance of this theory, Chinese medicines with heat-clearing and detoxifying or tonic effects are commonly used in the treatment of the lung and intestinal diseases by regulating lung-bowel mucosal immunity and they can be candidate drugs to treat lung/intestinal diseases simultaneously. However, the existing studies on immune regulation are mainly focused on the expression levels of sIgA and cytokines, as well as the changes in the number of immune cells such as innate lymphocytes and B lymphocytes. While the following aspects need further investigation: the airway/intestinal mucous hypersecretion, the functional changes of pulmonary and intestinal mucosal barrier immune cells, the dynamic process of lung/intestinal mucosal immune interaction, the intervention effect of local pulmonary/intestinal microecology, the correlation and biological basis between the heat-clearing and detoxifying effect and the tonic effect, and its regulation of pulmonary/intestinal mucosal immunity. In this paper, we try to analyze the internal relationship between lung and intestine related diseases from the point of view of the common mucosal immune system of lung and intestine, and summarize the characteristics and rules of traditional Chinese medicine compound and its active ingredients, which have regulatory effect on lung and intestine mucosal immune system, so as to further explain the theoretical connotation of “lung and large intestine being interior-exteriorly related” and provide reference for the research and development of drugs for related diseases.

[Key words] Lung-gut axis; Immunity, mucosal; Innate lymphocytes; Lymphocyte homing; Traditional Chinese medicine treatment

[J Zhejiang Univ (Med Sci), 2020,49(6):665-678.]

“肺与大肠相表里”理论是中医藏象学说的的重要内容,是中医对“肺”与“大肠”在解剖位置、经络循行、生理病理之间辩证统一关系的高度概括,是中医整体观的体现。肺与大肠的关系首见于《灵枢·本输》:“肺合大肠,大肠者,传导之腑”;《灵枢·经脉》记载了手太阴肺经和手阳

明大肠经的络属关系。两者在生理上相互依存,在气机宣降和津液输布功能中相互协调、相互制约,共同维持机体健康;肺气的肃降有助于大肠传导功能的发挥,而大肠的传导功能正常,又有助于肺气的肃降^[1]。病理上肺与大肠相互影响、相互传变,肺之肃降生理功能的改变会对

大肠腑的顺降气机产生明显的影响,介导由肺及肠的病理改变;而大肠传导功能发生异常可引发咳嗽、气喘等肺失宣肃的症状^[2]。研究证明,50%成年炎症性肠病患者存在肺炎或肺功能受损现象^[3-5],肠病可影响肺中降钙素基因相关肽、P物质、血管活性肠肽等的表达^[6],肺内气道高敏反应可导致肠道炎症发生^[7-8]。治疗上两者相互为用,肠病治肺而愈,肺病治肠而愈^[9-14]。近年来,越来越多的证据验证了“肺与大肠相表里”现象客观存在及其科学性^[15-17],应用该理论指导2019冠状病毒病^[18-19]、溃疡性结肠炎^[20]等难治病的治疗疗效受到研究者们关注。本文试从肺、肠共同拥有的黏膜免疫系统切入,从黏膜固有淋巴细胞归巢角度分析肺肠相关疾病的内在联系,希望该理论在肺、肠疾病治疗中发挥更好的指导作用;同时从文献中筛选对肺、肠黏膜免疫具有调节作用的中药复方及其有效成分,分析其作用特点和规律,为“肺与大肠相表里”理论内涵的深入阐释及相关疾病治疗药物的研发提供参考。

1 “肺与大肠相表里”的生物学基础

从胚胎发育的角度,肺、气管由肠的前肠发展而来,呼吸道上皮和膜体由原肠内胚层分化而成,肺和结肠、回肠在胚胎组织的发生上具有同源性^[21-22]。肺和肠道是直接与外界接触的器官,两者均具有典型的、由上皮和固有层组成的黏膜结构,同属公共黏膜免疫系统。肺、肠黏膜均能分泌的分泌型免疫球蛋白A(sIgA)是体现“肺与大肠相表里”的重要分子生物学基础^[23]。菌群可能是联系肺-肠的物质基础之一^[24]。肠道微生物群可影响远端肺部的免疫应答^[25],肠道微生物种类和代谢产物的改变与肠/肺免疫异常、炎症发生以及过敏、哮喘、慢性阻塞性肺疾病、急性呼吸窘迫综合征和肺癌等肺部疾病的发展有关^[26-27]。在呼吸道流感病毒感染的小鼠模型中,招募到小肠的肺源CCR9⁺CD4⁺T细胞产生的 γ 干扰素通过调节肠道菌群的组成,介导肠道疾病的发生^[28];肺树突状细胞能够诱导高水平的肠道归巢整合素,使T细胞迁移到肠道,介导肠道保护性免疫^[29]。综上可知,肺与大肠解剖上的同质性促使了肺-肠黏膜免疫间的相关性,肠道和肺之间存在密集的免疫对话,

肺-肠轴是由肠道和肺部微生物及其局部和长期免疫相互作用所形成的一种特殊联系,黏膜免疫是肺与大肠共享生理病理的基础之一。

2 肺与大肠共享生理病理的主要免疫调节机制

黏膜免疫是连接肺和肠道的桥梁,肺-肠可分别作为诱导部位和效应部位,通过黏膜淋巴细胞归巢建立共同黏膜防御机制^[23]。固有淋巴细胞(innate lymphoid cells, ILC)是一种具有获得性免疫功能的免疫细胞,其在调节免疫防御、组织修复、代谢平衡和炎症反应中具有重要作用。ILC根据分泌细胞因子的不同,分为分泌 γ 干扰素的ILC1,分泌IL-5、IL-9、IL-13的ILC2以及分泌IL-17、IL-22的ILC3^[30]。其中,ILC2和ILC3尤其是ILC3与“肺与大肠相表里”关系密切^[31-32]。

ILC2主要位于肠道和呼吸道黏膜组织。肠道中,ILC2响应上皮细胞分泌的细胞因子IL-25,协同Th2细胞产生IL-5、IL-9等细胞因子,并招募嗜酸/嗜碱性粒细胞、肥大细胞及产生IgE的B细胞,促进肠道炎症的产生^[7]。肠道中的ILC2可通过肠系膜淋巴系统进入血液循环,从肠道迁移至肺部,参与肺部的免疫炎症反应^[33]。肺内气道高敏反应呈ILC2依赖性,ILC2产生的IL-13通过促进肺部激活的树突状细胞进入引流淋巴结,使幼稚T细胞向Th2分化,产生获得性Th2细胞免疫^[8]。

ILC3包括产生IL-22的ILC3^[34](又称ILC22、NK22、NKR-LTi、NCR22^[35]),产生IL-17A和 γ 干扰素的NCR⁻IL-17A⁺IFN- γ ⁺ILC3^[36]以及NCR⁻IL-17A⁺ILC3^[37]。ILC3主要分布于肺、肠黏膜屏障,通过分泌细胞因子与适应性免疫系统相互作用,在机体免疫和黏膜屏障稳态调节中起重要作用^[38-40]。ILC3是人类肺组织中最常见的淋巴细胞类群,在慢性阻塞性肺疾病患者中表达明显增加^[41];ILC3及其分泌的IL-17、IL-22和巨噬细胞集落刺激因子参与病毒感染、细菌性肺炎及慢性阻塞性肺疾病等肺部疾病的免疫调节^[42]、上皮细胞稳态的维持以及炎性损伤后上皮细胞的修复和再生^[39]。在肺炎克雷伯菌介导的肺部感染中,被招募到肺部的趋化因子C-C-基元受体2(CCR2)阳性炎性单核细胞分泌TNF- α ,通过上调肺上皮细胞表达趋化因子CC趋化因子配体20(CCL20),促进分布在肠道的ILC3募集到肺感染

部位并分泌 IL-17A, 增强单核细胞介导的细菌摄取和杀伤作用^[43]。在肠道, ILC3 分泌的 IL-22 和信号传导和激活因子 3 (STAT3) 对控制急性肠黏膜细菌感染、维持肠道免疫至关重要, 视黄酸受体相关孤儿受体 γ t (ROR γ t) 阳性 ILC3 的功能及 IL-22 的转录受 STAT3 信号通路调节^[44]; ROR γ t 阳性 ILC3 是肠道中巨噬细胞集落刺激因子 (Csf2) 的主要来源, 肠道共生菌驱动的边缘中性粒细胞池 (MNP)-ILC-Csf2 轴是肠道内免疫稳态的关键调节因子^[45]。值得注意的是, 由 ILC3 异常分泌的 IL-17 可导致哮喘、肺炎以及肺纤维化等呼吸道病理改变^[46], 介导气道高反应性^[38]及持续的肠道炎症反应^[47-49]。

除 ILC 介导的黏膜免疫调节机制外, 肺肠之间还存在微生物介导的免疫调节作用^[50]。肠系膜淋巴系统是肺和肠之间的重要通道, 完整的细菌及其片段或代谢物 (如短链脂肪酸) 可通过它跨肠屏障移位, 进入体循环, 调节肺的免疫应答^[51-53]。幽门螺杆菌提取物通过诱导 Batf3 依赖的肠道 CD103⁺ CD11b⁻ 树突状细胞在肺部富集及分泌 IL-10 可改善过敏性哮喘症状^[54-55]; 粪菌移植在有效治疗肺炎继发抗生素相关性腹泻的同时, 对肺炎也有缓解作用^[56]。由上述可知, 以 ILC3、ILC2 为代表的 ILC 及肺、肠微生物是“肺与大肠相表里”共享生理病理的黏膜免疫关键调节因子和潜在作用靶点。

3 肺与大肠病理传变的固有淋巴细胞迁移归巢调节机制

黏膜淋巴细胞归巢是黏膜免疫的重要活动之一。黏膜淋巴细胞表面的归巢受体与位于黏膜部位血管内皮细胞上的黏膜地址素之间的特异识别, 是黏膜淋巴细胞定向迁移以及肺、肠黏膜组织间建立共同黏膜免疫防御或病理传变的生物学基础^[7, 32, 48]。研究表明, 肠 ILC3 高表达趋化因子受体 (CCR) 9, 肠系膜淋巴结 T-bet 阴性 ILC3 和 T-bet 阳性 ILC3 中高表达 CCR7, CCR7^{-/-} 小鼠肠系膜淋巴结、CCR9^{-/-} 小鼠小肠及 Itg7 β ^{-/-} 小鼠结肠中 ILC3 分布数量下降; 黏膜树突状细胞分泌的视黄酸能诱导肠归巢受体 CCR9 和 α 4 β 7 表达, 促使 CD90⁺ CD127⁺ ILC 中 CCR7⁺ CCR9⁻ α 4 β 7⁻ 向 CCR7⁻ CCR9⁺ / α 4 β 7⁻ 转变, 诱导外周血中的 ILC3 向小肠和结肠迁移; ILC3 及其归巢受体能有

效恢复维生素 A 缺乏宿主的黏膜免疫缺陷^[57]。肠壁 CX3CR1⁺ 髓细胞通过表达 CXCL16 与 CXCR6⁺ NKp46⁺ ILC3 相互作用, 促进 ILC3 在肠道的聚集及分泌 IL-23 的树突状细胞诱导活化^[58]。结肠炎中, ILC3 分泌的巨噬细胞集落刺激因子招募髓系炎性单核细胞在肠道聚集介导了结肠炎的进展, 阻断巨噬细胞集落刺激因子可抑制 ILC3 从肠道固有层隐窝斑中的动员及活化^[59]。此外, 非特异性归巢受体也可促使淋巴细胞介导结肠炎中肺、肠的病理改变。在炎症性肠病活动性炎症期间, 表达非组织特异性趋化因子受体 CXCR3、CCR5 和 CCR2 的 ILC 在肠道黏膜富集, 这些细胞通过系统内循环, 错误归巢到肺组织, 促进了炎症性肠病的淋巴细胞性肺炎^[60-61]; 而 CCR7⁺ 记忆 T 细胞的错误归巢可有效激活归巢部位的树突状细胞, 并在再次刺激后向 CCR7⁻ 效应细胞分化, 介导炎症产生^[62]。

肺和肠道树突状细胞介导了 ILC 在肠道-肺黏膜免疫系统间的迁移和归巢^[29, 57]。在新生期特定发育窗口内的肠道共生菌暴露对小鼠肺黏膜免疫发育具有重要意义。新生小鼠肠道 CD103⁺ CD11b⁺ 树突状细胞从共生菌中捕获抗原, 诱导肺归巢信号 CCR4 在 IL-22⁺ ILC3 上表达, 促进 IL-22⁺ ILC3 向肺部转运及积累, 促进肺 IL-22 依赖的黏膜防御, 增强新生小鼠对肺炎的抵抗力; 共生细菌破坏可导致新生小鼠肺中产生 IL-22 的免疫细胞功能发生持久变化, 从而增加对肺炎的易感性^[25]。荚膜组织胞浆菌感染小鼠给予 TNF- α 拮抗剂可诱导肠道独有的 CD11b⁺ CD103⁺ 树突状细胞通过干扰素调节因子 4 (IRF4) 和 Notch2 依赖的途径从肠道经血液迁移到肺, 并通过分泌视黄酸诱导外周调节性 T 细胞向肺部聚集, 增加小鼠对荚膜组织胞浆菌的易感性; 阻止 CD11b⁺ CD103⁺ 树突状细胞从肠道到肺部的迁移或能防止中和 TNF- α 介导的细菌易感性^[63]。炎症性肠病患者肠道炎症黏膜 CD103⁺ 树突状细胞数量减少与其迁移有关, 给予 TNF- α 拮抗剂阿达木单抗能有效逆转此现象^[64-65]。可见, 调节肺、肠炎症性疾病中肺、肠黏膜 ILC 迁移归巢, 能有效改善“肺”与“大肠”间的病理传变, 阻断肺病及肠或肠病及肺过程。

4 基于“肺与大肠相表里”的中医药实践及其黏膜免疫调节作用

4.1 基于“肺与大肠相表里”的临床实践及现代研究

临床研究表明,宣肺通便方治疗功能性便秘疗效显著^[14];采用粪菌移植技术治疗肺炎继发抗生素相关性腹泻能有效改善肺部炎症及结肠溃疡,减轻腹痛、腹泻症状^[56];治疗溃疡性结肠炎时佐以补肺中药,可提高治愈率,降低复发率^[66];泻下中药复方——大承气汤可改善急性呼吸窘迫综合征患者的氧合指数和肺水肿,降低机械通气的并发症和患者病死率^[13];通腑解毒汤辅助西药治疗小儿重症肺炎可提高疗效、缩短病程^[67];泻肺通腑方药能降低老年重症肺炎合并胃肠功能障碍患者的肺部感染评分,缩短抗生素暴露、机械通气时间,提高综合疗效^[68]。苏子降气汤合宣白承气汤及宣降汤可分别用于治疗慢性阻塞性肺疾病及慢性支气管炎合并功能性便秘者^[69]。

现代药理研究表明,“肺肠同治”代表方剂宣白承气汤能有效降低脂多糖诱导的急性肺损伤大鼠肺组织P物质水平,改善肺水肿及肺组织病理学改变^[9];能降低脂多糖加熏香烟诱导的慢性阻塞性肺疾病模型大鼠外周血及肺泡灌洗液中细胞因子水平,改善肺部炎症反应^[17]。灌胃给予容积性泻下药芒硝能有效降低卵清蛋白诱导的过敏性哮喘小鼠气道阻力及肺泡灌洗液中嗜酸性粒细胞、淋巴细胞总数及血清IgE含量,抑制气道炎症^[70]。肠道疾病治疗方药葛根芩连汤能有效改善脂多糖诱导的急性肺损伤小鼠肺水肿及微血管渗透性,下调TNF- α 、IL-1 β 和IL-6水平,抑制肺部炎症反应及肺上皮细胞和内皮细胞凋亡^[71];大承气汤能降低哮喘及肺肠合并模型大鼠外周血淋巴细胞中Th17淋巴细胞比例及血清IL-6、IL-17水平,调节Th17与调节性T细胞的平衡,减少哮喘发生^[10];健脾固肠方通过减少肺癌小鼠肠道淋巴组织调节性T细胞、Th17细胞相关叉头框蛋白P3(FoxP3)、ROR γ t转录因子的表达,调节肠道免疫平衡,抑制肺癌侵袭转移^[12]。黄芪桔梗汤从肺论治能有效降低2,4,6-三硝基苯磺酸(TNBS)-乙醇诱导的溃疡性结肠炎大鼠肺与结肠组织黏膜中sIgA和IL-4水平,减轻肺和结肠组织病理损伤^[11];鱼腥草多糖能抑制甲型H1N1流感病毒小

鼠肺组织TLR4和NF- κ B蛋白表达及TNF- α 、IL-6、IFN- α 等细胞因子分泌,改善肺组织损伤,增加肠道sIgA分泌及肠黏液中IgA水平,上调肠上皮紧密连接蛋白闭锁小带蛋白1(ZO-1)表达,保护肠道机械及黏膜屏障,实现肺肠同治^[72]。上述研究表明,中药复方及其活性成分可通过调节肺、肠相关免疫反应,抑制炎症反应、改善黏膜屏障损伤等,阻断肺-肠间的病理传变,实现肺病治肠而愈和肠病治肺而愈。

4.2 中药复方及其活性成分对肺、肠黏膜的免疫调节作用

4.2.1 对生理状态肠黏膜免疫的调节作用 中药复方及其多糖部位对正常机体具有适度的免疫调节作用。加味四君子汤能升高健康仔猪血清IFN- γ 、IL-2、IL-4、IL-6水平,促进肠黏膜上皮及固有层sIgA蛋白和mRNA表达水平及sIgA分泌,增强仔猪机体免疫机能^[73]。中药四黄提取物、黄芪多糖能增加家禽肠道黏膜淋巴细胞及IgA⁺细胞数量,促进IgA分泌,提高肠道免疫功能^[74-75];板蓝根多糖、枸杞多糖、玉屏风散多糖可通过增加小鼠小肠黏膜上皮内淋巴细胞、杯状细胞、肥大细胞及IgG⁺、sIgA⁺细胞数量,增加外周血CD3⁺、CD4⁺、CD8⁺T淋巴细胞数量,促进IL-2、sIgA的分泌,增强免疫作用^[76-78];人参多糖和猪苓多糖在体外能活化肠黏膜派氏集合淋巴结中T淋巴细胞,诱导 γ 干扰素生成,发挥免疫促进活性^[79]。

4.2.2 对环磷酰胺致免疫功能低下状态肺、肠黏膜免疫的调节作用 补益类中药及其多糖成分能改善环磷酰胺诱导的肺、肠黏膜免疫功能低下。玉屏风散能增强环磷酰胺致免疫功能低下小鼠腹腔巨噬细胞吞噬功能、溶血素抗体生成,促进呼吸道和消化道IgA分泌;玉屏风散多糖能增加免疫功能低下小鼠肠黏膜派氏集合淋巴结数量及IgA⁺、CD3⁺细胞数,激活肠道黏膜免疫,提高肠道IgA分泌水平^[80],并能促进淋巴细胞向肺、肠黏膜归巢,增强NK细胞活性,改善环磷酰胺介导的免疫损伤^[81]。黄芪多糖^[82]、太子参多糖^[83]、“芪苓”制剂多糖^[84]能改善环磷酰胺致免疫功能低下小鼠肠道菌群结构,增加小肠黏膜派氏集合淋巴结面积及肺、肠道上皮淋巴细胞和杯状细胞数,促进sIgA、IL-2、IL-6、 γ 干扰素分泌,改善环磷酰胺诱导的肠道黏膜损伤。

4.2.3 对病理状态肺、肠黏膜免疫的调节作用

由清热解毒类中药组成的中药复方和活性成分对各类致病因素介导的肺、肠黏膜局部免疫功能异常具有良好的调节作用。在肺黏膜免疫调节方面,中药退热方(石膏 20 g,知母、黄芩、玄参、柴胡、栀子各 10 g,射干、桔梗各 5 g)能提高甲型流感患儿 sIgA 与白蛋白比值,增强呼吸道黏膜免疫功能,其退热时间短于应用奥司他韦的患儿^[85-86];解表方麻黄汤(麻黄 9 g,桂枝、杏仁各 6 g,甘草 3 g)、银翘散(连翘、金银花各 30 g,苦桔梗、薄荷、牛蒡子各 18 g,生甘草、淡豆豉各 15 g,竹叶、芥穗各 12 g)能提高寒冷刺激诱导的上呼吸道黏膜免疫功能低下模型小鼠唾液 sIgA 含量及溶菌酶活性,降低链球菌肺炎小鼠死亡率,延长生存时间^[87];银莱汤(金银花、莱菔子、黄芩、连翘、鱼腥草、前胡、瓜蒌)能增强食积复合 FM1 流感病毒感染小鼠肠黏膜局部免疫功能,促进 sIgA 分泌,适度调节 TNF- α 、IL-10 等细胞因子水平,改善肠黏膜屏障损伤,防治食积呼吸道感染疾病^[88]。疏风解毒胶囊能降低肺炎链球菌致肺炎大鼠外周血 B 淋巴细胞、CD8⁺ 比例和 IL-1 β 、TNF- α 、IFN- α 等细胞因子及 IgM 等免疫球蛋白水平,升高外周血 CD4⁺/CD8⁺ 及 NK 细胞比例,抑制过度免疫介导的肺部炎症反应^[89]。人参皂苷 Rg1 能减少肺组织中中性粒细胞及 M2 型巨噬细胞浸润,抑制 NF- κ B 磷酸化,保护脂多糖诱导的急性肺损伤^[90]。

在肠黏膜免疫调节方面,七味白术散可增加肠黏膜 sIgA 表达,改善肠黏膜炎性病变,对抗抗菌药物联合番泻叶致菌群失调小鼠肠黏膜损伤^[91]。藿香正气液能上调结肠灌注乙酸致感染后肠应激综合征大鼠血清 IL-10 水平,促进 sIgA 分泌,抑制结肠黏膜组织 NF- κ B p65、p38 MAPK、细胞间黏附分子 1 表达,上调结肠黏膜 ZO-1 等表达,改善结肠上皮细胞超微结构,保护肠黏膜屏障损伤^[92];藿香正气双向胶囊能增加福氏痢疾杆菌和鼠伤寒沙门菌所致腹泻小鼠外周血及肠道黏膜派氏集合淋巴结 CD8⁺ T 淋巴细胞数,降低 CD4⁺/CD8⁺ 比例及 TNF- α 水平,改善腹泻症状^[93];通腑颗粒能增加尾静脉注射脂多糖致内毒素血症大鼠肠黏膜树突状细胞和 CD4⁺、CD8⁺ T 细胞及 IgA⁺ B 细胞数量,调节 Th1/Th2 细胞比例,减少淋巴细胞凋亡,改善肠黏膜免疫损伤^[94]。大豆异黄酮^[95],人参皂苷 Rb3、Rd^[96] 能增加肥胖大鼠及 Apc^{min/+} 小鼠小肠黏膜上皮内淋巴细胞和

杯状细胞的数量,改善肠黏膜免疫屏障结构;巴豆霜-大黄多糖药对能改善溃疡性结肠炎大鼠 T 淋巴细胞亚群比例,降低黏膜地址素细胞黏附分子(MadCAM-1)和细胞间黏附分子 1 的表达,减少 CD8⁺ T 淋巴细胞过度归巢,改善肠黏膜免疫功能亢进,改善肠道炎症反应^[97];小檗碱可降低糖尿病大鼠肠道肠系膜淋巴结中调节性 T 细胞及 CD11b⁺ CD68⁺ 细胞比例,抑制 IL-1 β 和 TNF- α mRNA 表达,上调 IL-4 和 IL-10 mRNA 水平^[98];姜黄素能诱导 CD4⁺ T 细胞向 CD4⁺ CD25⁺ Foxp3⁺ 调节性 T 细胞及分泌 IL-10 的 I 型调节性 T 细胞分化,促进肠固有层分泌 TGF- β 和视黄酸,激活肠上皮细胞及 ILC 分泌 IL-25、IL-33、IL-22 和 IL-17,抑制肠道炎症^[99-100];黄芩苷能调节肺、肠黏膜 sIgA 分泌水平及 CD4⁺/CD8⁺ 淋巴细胞比例,改善轮状病毒诱导的肺、肠病理损伤^[101]。

同时,中药对化疗及创伤致肠黏膜免疫损伤也有保护作用。生姜泻心汤(生姜、大枣各 12 g,党参、黄芩、半夏、甘草各 9 g,干姜、黄连各 3 g)通过上调伊立替康化疗后大鼠肠黏膜 CD4⁺ 和 CD8⁺ T 淋巴细胞数及 sIgA 水平,改善肠黏膜免疫屏障功能,从而预防伊立替康诱导的迟发性腹泻^[102];芪黄煎剂(黄芪、党参、白术各 20 g,丹参 15 g,黄芩 12 g,大黄、枳实、厚朴各 10 g)能促进胃切除术后大鼠小肠黏膜免疫屏障 IgA⁺ B 淋巴细胞和 CD3⁺、CD4⁺、CD8⁺ T 淋巴细胞增殖、分化及 sIgA 分泌^[103],上调肠淋巴细胞表面归巢受体 α 4 β 7、L 选择素和淋巴细胞功能相关抗原 1(LFA-1)阳性细胞数量及 mRNA 相对表达量^[104],增加肠淋巴细胞归巢 T、B 细胞数量^[105],减轻创伤后肠道免疫屏障功能损伤。

5 结 语

“肺与大肠相表里”理论自建立以来,与临床应用互动发展。在该理论指导下,中医药在严重急性呼吸综合征(SARS)^[106]、2019 冠状病毒病^[18,107]等传染病的防治中发挥了重要作用。邱海波教授在介绍 2019 冠状病毒病中西医结合治疗经验中也提到“肺与大肠相表里”的中医原理,并指出了该理论与现代医学的共通之处^[108]。随着中医理论和现代医学关联性的深入分析,“肺与大肠相表里”理论或可指导西医临床肺、肠相关疾病的治疗。

现代药理研究表明,肺、肠黏膜中的趋化因子、归巢受体、sIgA、CD4⁺、CD8⁺T 淋巴细胞及肺、肠道微生物等可能为“肺与大肠相表里”的物质基础,而肺、肠黏膜间 ILC 及树突状细胞等免疫细胞的迁移、归巢及其介导的炎症反应是肺-肠之间病理传变的主要机制。现有研究已证实补益类、清热解毒类中药复方及其有效部位和活性成分可通过增加黏膜上皮淋巴细胞和杯状细胞数使黏膜屏障结构趋于完整、促进黏膜 sIgA 分泌及淋巴细胞归巢等,对肺、肠黏膜免疫功能异常介导的相关疾病具有较好疗效。但现有研究主要关注于 sIgA、细胞因子表达水平及 ILC 等免疫细胞数量的变化,而对与之相关的气道/肠道黏液高分泌、肺及肠道黏膜屏障免疫细胞功能改变、肺-肠黏膜免疫相互作用动态过程及肺/肠局部微生态的干预作用等的研究相对较少;此外,关于清热解毒类中药和补益类中药对肺、肠黏膜免疫调节作用的异同点、所治疾病的特点及其特征作用机制,也未有相关的比较研究。上述未解之处可作为“肺肠同治”中药后续研究的方向之一。

中医药是我国具有原创优势的科技资源,是提升我国原始创新能力的“宝库”之一。“肺与大肠相表里”理论历久弥新,对肺-肠黏膜屏障的差异性、现代疾病过程中肺-肠道黏液高分泌与传统肺与大肠“津液相求”理论及其与黏膜免疫调节间的相关性的深入研究,以及“肺肠同治”确有疗效的清热解毒类中药和补益类中药及复方所具有的清热解毒、补益功效与其调节肺-肠黏膜免疫作用间的相关性和生物学基础的阐明,将有助于促进“肺与大肠相表里”理论现代科学内涵的阐释,使其在一些新发、难治疾病的防治中发挥更大的作用。

参考文献

- [1] 李 磊,孙广仁,张庆祥,等.“气机升降”在“肺合大肠”关系中的生理意义[J]. 山东中医杂志,2013,32(10):699-700,710. DOI:10.16295/j.cnki.0257-358x.2013.10.003.
LI Lei, SUN Guangren, ZHANG Qinxiang, et al. The physiological significance of lift and drop of Qi movement in the lung together the large intestine[J]. **Shandong Journal of Traditional Chinese Medicine**, 2013,32(10):699-700,710. DOI:10.16295/j.cnki.0257-358x.2013.10.003. (in Chinese)
- [2] 马师雷. 基于三部《名医类案》和红外热像技术分析“肺与大肠相表里”理论的证治规律[D]. 北京:北京中医药大学,2013.
MA Shilei. Syndrome and therapeutic principles analysis of theory on “the lung and large intestine are exterior-interiorly related” based on three sections of Mingyi Lei'an and infrared thermal imaging technology [D]. Beijing: Beijing University of Chinese Medicine,2013. (in Chinese)
- [3] YAZAR A, ATIS S, KONCA K, et al. Respiratory symptoms and pulmonary functional changes in patients with irritable bowel syndrome [J]. **Am J Gastroenterol**,2001,96(5):1511-1516. DOI:10.1111/j.1572-0241.2001.03748.x.
- [4] CEYHAN B B, KARAKURT S, CEVIK H, et al. Bronchial hyperreactivity and allergic status in inflammatory bowel disease[J]. **Respiration**,2003,70(1):60-66. DOI:10.1159/000068407.
- [5] DOUGLAS J G, MCDONALD C F, LESLIE M J, et al. Respiratory impairment in inflammatory bowel disease: does it vary with disease activity? [J]. **Respir Med**,1989,83(5):389-394. DOI:10.1016/s0954-6111(89)80070-8.
- [6] 郑秀丽,杨 宇,唐洪屈,等.从肺与大肠的特异相关性探讨“肺与大肠相表里”[J]. **中华中医药杂志**,2013,28(5):1492-1495.
ZHENG Xiuli, YANG Yu, TANG Hongqu, et al. Discussion of “the interior and exterior relationship between lung and large intestine” from the perspective of specific correlation between lung and large intestine [J]. **China Journal of Traditional Chinese Medicine and Pharmacy**,2013,28(5):1492-1495. (in Chinese)
- [7] CAMELO A, BARLOW J L, DRYNAN L F, et al. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13 [J]. **J Gastroenterol**,2012,47(11):1198-1211. DOI:10.1007/s00535-012-0591-2.
- [8] HALIM T Y, STEER C A, MATHÄ L, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation[J]. **Immunity**,2014,40(3):425-435. DOI:10.1016/j.immuni.2014.01.011.
- [9] 童晓萍,何德平,林 琳.“从肠论治”对急性肺损伤大鼠 P 物质含量影响[J]. **辽宁中医药大学学报**,2016,18(9):33-35. DOI:10.13194/j.issn.1673-842x.2016.09.009.
TONG Xiaoping, HE Deping, LIN Lin. Influence of “Treatment based on large intestine” on contents of substance P in rats with acute lung injury [J]. **Journal of Liaoning University of Traditional Chinese Medicine**,2016,18(9):33-35. DOI:10.

- 13194/j. issn. 1673-842x. 2016. 09. 009. (in Chinese)
- [10] 李继红,王小莉,霍吉尔,等. 大承气汤对支气管哮喘及肺肠合病 Treg/TH17 免疫机制的作用[J]. 吉首大学学报(自然科学版), 2019, 40(4): 88-92. DOI:10. 13438/j. cnki. jdzk. 2019. 04. 017.
LI Jihong, WANG Xiaoli, HUO Ji'er, et al. Effect of Dachengqi decoction on the immunologic mechanism of Treg/TH17 in bronchial asthma and lung-intestinal disease[J]. **Journal of Jishou University (Natural Sciences Edition)**, 2019, 40(4): 88-92. DOI: 10. 13438/j. cnki. jdzk. 2019. 04. 017. (in Chinese)
- [11] 孙慧怡,刘大铭,张雯,等. 从肺论治、从肠论治法对溃疡性结肠炎大鼠肺与结肠组织白细胞介素4、分泌型免疫球蛋白A表达的影响[J]. 环球中医药, 2019, 12(11): 1619-1624. DOI: 10. 3969/j. issn. 1674-1749. 2019. 11. 001.
SUN Huiyi, LIU Daming, ZHANG Wen, et al. Effects of lung treatment and intestinal treatment on the expression of IL-4 and s-IgA in lung and colon tissues of ulcerative colitis rats [J]. **Global Traditional Chinese Medicine**, 2019, 12(11): 1619-1624. DOI:10. 3969/j. issn. 1674-1749. 2019. 11. 001. (in Chinese)
- [12] 蒋海燕,张士强,杨蕴,等. 基于“肺与大肠相表里”研究健脾固肠方通过调节肠道免疫平衡抑制肺癌小鼠肿瘤转移的机制[J]. 上海中医药杂志, 2020, 54(3): 91-96. DOI:10. 16305/j. 1007-1334. 2020. 03. 024.
JIANG Haiyan, ZHANG Shiqiang, YANG Yun, et al. Mechanisms of Jianpi Guchang recipe in inhibiting metastasis of lung cancer in mice by regulating intestinal immune balance based on the theory of “the lung and the large intestine being interior-exteriorly related” [J]. **Shanghai Journal of Traditional Chinese Medicine**, 2020, 54(3): 91-96. DOI: 10. 16305/j. 1007-1334. 2020. 03. 024. (in Chinese)
- [13] 郭秀芹. 大承气汤治疗急性呼吸窘迫综合征的临床探究[D]. 济南: 山东中医药大学, 2017.
GUO Xiuqin. The clinical exploration of Dachengqi decoction for the patients with acute respiratory distress syndrome[D]. Jinan: Shangdong University of Traditional Chinese Medicine, 2017. (in Chinese)
- [14] 卢建珍,裴静波,潘建锋,等. 基于“肺与大肠相表里”理论的宣肺通便方治疗功能性便秘的疗效及对血清 SP、NO 水平影响研究[J]. 广州中医药大学学报, 2020, 37(2): 233-238. DOI: 10. 13359/j. cnki. gzxhtcm. 2020. 02. 007.
LU Jianzhen, PEI Jingbo, PAN Jianfeng, et al. Therapeutic effect of Xuanfei Tongbian recipe prescribed on basis of theory of lung and large intestine being interior-exteriorly related for treatment of functional constipation and its influence on serum substance P and nitric oxide levels[J]. **Journal of Guangzhou University of Traditional Chinese Medicine**, 2020, 37(2): 233-238. DOI:10. 13359/j. cnki. gzxhtcm. 2020. 02. 007. (in Chinese)
- [15] 田在善,沈长虹,李东华,等. 大承气汤对便秘大鼠肺泡巨噬细胞活力的影响——“肺与大肠相表里”的实验研究[J]. 天津中医, 1992, (4): 19-22.
TIAN Zaishan, SHENG Changhong, LI Donghua, et al. Effects of Dachengqi decoction on the activity of alveolar macrophage in rats with constipation—An experimental study on “lung and large intestine being interior-exteriorly related” [J]. **Tianjin Journal of Traditional Chinese Medicine**, 1992, (4): 19-22. (in Chinese)
- [16] 王坦,张前,李宇航,等. “通利大肠”对 COPD 大鼠细胞因子含量的影响[J]. 北京中医药大学学报, 2013, 36(2): 104-107. DOI: 10. 3969/j. issn. 1006-2157. 2013. 02. 009.
WANG Tan, ZHANG Qian, LI Yuhang, et al. Influence of dredging large intestine on content of cytokines in rats with chronic obstructive pulmonary disease [J]. **Journal of Beijing University of Traditional Chinese Medicine**, 2013, 36(2): 104-107. DOI: 10. 3969/j. issn. 1006-2157. 2013. 02. 009. (in Chinese)
- [17] 时晨,林丽丽,谢彤,等. 基于“肺-肠”轴探讨肺、肠微生态对肺部疾病的影响[J]. 南京中医药大学学报, 2020, 36(2): 168-173. DOI:10. 14148/j. issn. 1672-0482. 2020. 0168.
SHI Chen, LIN Lili, XIE Tong, et al. The role of the lung-gut axis and the lung and gut microorganism in pulmonary disease [J]. **Journal of Nanjing University of Traditional Chinese Medicine**, 2020, 36(2): 168-173. DOI:10. 14148/j. issn. 1672-0482. 2020. 0168. (in Chinese)
- [18] 刘若阳,余德海,党思捷,等. 从“肺与大肠相表里”论治新型冠状病毒肺炎[J]. 成都中医药大学学报, 2020, 43(1): 14-16, 41. DOI:10. 13593/j. cnki. 51-1501/r. 2020. 01. 014.
LIU Ruoyang, YU Dehai, DANG Sijie, et al. Treating corona virus disease 2019 from theory of “lung and large intestine being interior-exteriorly related” [J]. **Journal of Chengdu University of Traditional Chinese Medicine**, 2020, 43(1): 14-16, 41. DOI:10. 13593/j. cnki. 51-1501/r. 2020. 01. 014. (in Chinese)
- [19] 唐凌,李少滨,袁敏,等. “肺与大肠相表里”理论在重型新型冠状病毒肺炎治疗中的应用探讨[J]. 上海中医药杂志, 2020, 54(4): 23-26. DOI: 10. 16305/j. 1007-1334. 2020. 04. 003.
TANG Ling, LI Shaobin, YUAN Min, et al. Application of the theory of “lung and intestine

- forming an exterior and interior relationship” to the treatment of severe COVID-19 [J]. **Shanghai Journal of Traditional Chinese Medicine**, 2020, 54 (4): 23-26. DOI: 10.16305/j.1007-1334.2020.04.003. (in Chinese)
- [20] 周敏红, 叶 柏. 叶柏教授从肺论治溃疡性结肠炎缓解期临床经验浅析[J]. **四川中医**, 2016, 34(2): 1-3. DOI: CNKI: SUN; SCZY. 0. 2016-02-001. ZHOU Minhong, YEI Bai. Professor Ye Bai's clinical experience in treating remission stage of ulcerative colitis based on lung theory[J]. **Journal of Sichuan of Traditional Chinese Medicine**, 2016, 34 (2): 1-3. DOI: CNKI: SUN; SCZY. 0. 2016-02-001. (in Chinese)
- [21] 刘 声, 刘晓燕, 李立华, 等. “肺与大肠相表里”的组织细胞学基础研究[J]. **中华中医药杂志**, 2012, 27(4): 1167-1170. LIU Sheng, LIU Xiaoyan, LI Lihua, et al. Histology “lung and large intestine being interior-exteriorly related” [J]. **China Journal of Traditional Chinese Medicine and Pharmacy**, 2012, 27 (4): 1167-1170. (in Chinese)
- [22] 刘 声, 刘晓燕, 郭霞珍. 从肺肠上皮组织细胞变化分析肺与大肠相表里的内涵[J]. **世界中医药**, 2014, 9(8): 1051-1054. DOI: 10.3969/j. issn. 1673-7202. 2014. 08. 026. LIU Sheng, LIU Xiaoyan, GUO Xiazhen. Analysis of the connotation of interior-exteriorly relation of the lung and large intestine from changes of the epithelial cells[J]. **World Chinese Medicine**, 2014, 9 (8): 1051-1054. DOI: 10.3969/j. issn. 1673-7202. 2014. 08. 026. (in Chinese)
- [23] 靳文学, 杨 宇. 从粘膜免疫系统看“肺与大肠相表里”[J]. **四川中医**, 2005, 23(12): 1-3. DOI: 10.3969/j. issn. 1000-3649. 2005. 12. 001. QI Wenxue, YANG Yu. Explanation of “interior-exteriorly relation of the lung and large intestine” from the perspective of mucosal immune system [J]. **Journal of Sichuan of Traditional Chinese Medicine**, 2005, 23 (12): 1-3. DOI: 10.3969/j. issn. 1000-3649. 2005. 12. 001. (in Chinese)
- [24] 徐天成, 吴晓亮, 裴丽霞, 等. 肺与大肠相表里的微生物生态学解释[J]. **中国微生态学杂志**, 2018, 30(1): 100-103. DOI: 10.13381/j. cnki. cjm. 201801025. XU Tiancheng, WU Xiaoliang, PEI Lixia, et al. Microecological interpretation of the lung-gut axis [J]. **Chinese Journal of Microecology**, 2018, 30 (1): 100-103. DOI: 10.13381/j. cnki. cjm. 201801025. (in Chinese)
- [25] GRAY J, OEHRLE K, WORTHEN G, et al. Intestinal commensal bacteria mediate lung mucosal immunity and promote resistance of newborn mice to infection[J]. **Sci Transl Med**, 2017, 9(376). DOI: 10.1126/scitranslmed. aaf9412.
- [26] MUKHERJEE S, HANIDZIAR D. More of the gut in the lung: how two microbiomes meet in ARDS[J]. **Yale J Biol Med**, 2018, 91(2): 143-149.
- [27] ZHANG D, LI S, WANG N, et al. The cross-talk between gut microbiota and lungs in common lung diseases[J]. **Front Microbiol**, 2020, 11: 301. DOI: 10.3389/fmicb. 2020. 00301.
- [28] WANG J, LI F, WEI H, et al. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation [J]. **J Exp Med**, 2014, 211(12): 2397-2410. DOI: 10.1084/jem. 20140625.
- [29] RUANE D, BRANE L, REIS B S, et al. Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract[J]. **J Exp Med**, 2013, 210(9): 1871-1888. DOI: 10.1084/jem. 20122762.
- [30] SPITS H, ARTIS D, COLONNA M, et al. Innate lymphoid cells--a proposal for uniform nomenclature [J]. **Nat Rev Immunol**, 2013, 13 (2): 145-149. DOI: 10.1038/nri3365.
- [31] 卢晨雨, 汪 浏. 三型固有淋巴细胞在肠道免疫中的作用[J]. **生命科学研究**, 2018, 22(2): 167-172. DOI: 10.16605/j. cnki. 1007-7847. 2018. 02. 011. LU Chenyu, WANG Lie. The role of ILC3 in intestinal immunity [J]. **Life Science Research**, 2018, 22 (2): 167-172. DOI: 10.16605/j. cnki. 1007-7847. 2018. 02. 011. (in Chinese)
- [32] MJÖSBORG J, RAO A. Lung inflammation originating in the gut [J]. **Science**, 2018, 359 (6371): 36-37. DOI: 10.1126/science. aar4301.
- [33] HUANG Y, MAO K, CHEN X, et al. SIP-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense[J]. **Science**, 2018, 359 (6371): 114-119. DOI: 10.1126/science. aam5809.
- [34] CELLA M, FUCHS A, VERMI W, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity[J]. **Nature**, 2009, 457 (7230): 722-725. DOI: 10.1038/nature07537.
- [35] SANOS S L, BUI V L, MORTHA A, et al. ROR γ and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46⁺ cells[J]. **Nat Immunol**, 2009, 10(1): 83-91. DOI: 10.1038/ni. 1684.
- [36] BUONOCORE S, AHERN P P, UHLIG H H, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology [J]. **Nature**, 2010, 464 (7293): 1371-1375. DOI: 10.1038/nature08949.
- [37] POWELL N, WALKER A W, STOLARCZYK E, et al. The transcription factor T-bet regulates intestinal

- inflammation mediated by interleukin-7 receptor⁺ innate lymphoid cells[J]. **Immunity**, 2012, 37(4): 674-684. DOI:10.1016/j.immuni.2012.09.008.
- [38] KIM C H, HASHIMOTO-HILL S, KIM M. Migration and tissue tropism of innate lymphoid cells [J]. **Trends Immunol**, 2016, 37(1): 68-79. DOI: 10.1016/j.it.2015.11.003.
- [39] SONNENBERG G F, FOUSER L A, ARTIS D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22 [J]. **Nat Immunol**, 2011, 12(5): 383-390. DOI: 10.1038/ni.2025.
- [40] KLOSE C S, KISS E A, SCHWIERZECK V, et al. A T-bet gradient controls the fate and function of CCR6-RORgammat⁺ innate lymphoid cells [J]. **Nature**, 2013, 494(7436): 261-265. DOI:10.1038/nature11813.
- [41] DE GROVE K C, PROVOOST S, VERHAMME F M, et al. Characterization and quantification of innate lymphoid cell subsets in human lung[J/OL]. **PLoS One**, 2016, 11(1): e0145961. DOI:10.1371/journal.pone.0145961.
- [42] ARDAIN A, PORTERFIELD J Z, KLØVERPRIS H N, et al. Type 3 ILCs in lung disease [J]. **Front Immunol**, 2019, 10: 92. DOI: 10.3389/fimmu.2019.00092.
- [43] XIONG H, KEITH J W, SAMILO D W, et al. Innate lymphocyte/Ly6C (hi) monocyte crosstalk promotes klebsiella pneumoniae clearance [J]. **Cell**, 2016, 165(3): 679-689. DOI:10.1016/j.cell.2016.03.017.
- [44] GUO X, QIU J, TU T, et al. Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection [J]. **Immunity**, 2014, 40(1): 25-39. DOI:10.1016/j.immuni.2013.10.021.
- [45] MORTHA A, CHUDNOVSKIY A, HASHIMOTO D, et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis [J]. **Science**, 2014, 343(6178): 1249288. DOI:10.1126/science.1249288.
- [46] GURCZYNSKI S J, MOORE B B. IL-17 in the lung: the good, the bad, and the ugly [J]. **Am J Physiol Lung Cell Mol Physiol**, 2018, 314(1): L6-L16. DOI:10.1152/ajplung.00344.2017.
- [47] TAKAYAMA T, KAMADA N, CHINEN H, et al. Imbalance of NKp44(+) NKp46(-) and NKp44(-) NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease [J]. **Gastroenterology**, 2010, 139(3): 882-892, 892e1-3. DOI:10.1053/j.gastro.2010.05.040.
- [48] EKEN A, SINGH A K, TREUTING P M, et al. IL-23R⁺ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism [J]. **Mucosal Immunol**, 2014, 7(1): 143-154. DOI:10.1038/mi.2013.33.
- [49] KIM M, GU B, MADISON M C, et al. Cigarette smoke induces intestinal inflammation via a Th17 cell-neutrophil axis [J]. **Front Immunol**, 2019, 10: 75. DOI:10.3389/fimmu.2019.00075.
- [50] ENAUD R, PREVEL R, CIARLO E, et al. The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks [J]. **Front Cell Infect Microbiol**, 2020, 10: 9. DOI:10.3389/fcimb.2020.00009.
- [51] TROMPETTE A, GOLLWITZER E S, YADAVA K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis [J]. **Nat Med**, 2014, 20(2): 159-166. DOI: 10.1038/nm.3444.
- [52] BINGULA R, FILAIRE M, RADOSEVIC-ROBIN N, et al. Desired turbulence? gut-lung axis, immunity, and lung cancer [J]. **J Oncol**, 2017, 2017: 5035371. DOI:10.1155/2017/5035371.
- [53] MCALEER J P, KOLLS J K. Contributions of the intestinal microbiome in lung immunity [J]. **Eur J Immunol**, 2018, 48(1): 39-49. DOI: 10.1002/eji.201646721.
- [54] ENGLER D B, REUTER S, VAN WIJCK Y, et al. Effective treatment of allergic airway inflammation with *Helicobacter pylori* immunomodulators requires BATF3-dependent dendritic cells and IL-10 [J]. **Proc Natl Acad Sci U S A**, 2014, 111(32): 11810-11815. DOI:10.1073/pnas.1410579111.
- [55] DICKSON R P, SINGER B H, NEWSTEAD M W, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome [J]. **Nat Microbiol**, 2016, 1(10): 16113. DOI:10.1038/nmicrobiol.2016.113.
- [56] 汤忠泉, 李云涛. 基于肺与大肠相表里理论采用粪菌移植治疗肺炎继发抗生素相关性腹泻 [J]. **中国中西医结合消化杂志**, 2020, 28(4): 268-271. DOI: 10.3969/j.issn.1671-038X.2020.04.06.
- TANG Zhongquan, LI Yuntao. Treatment of antibiotic associated diarrhea secondary to pneumonia by fecal bacteria transplantation based on the theory of "interior-exterior relationship of lung and large intestine" [J]. **Chinese Journal of Integrated Traditional and Western Medicine on Digestion**, 2020, 28(4): 268-271. DOI: 10.3969/j.issn.1671-038X.2020.04.06. (in Chinese)
- [57] KIM M H, TAPAROWSKY E J, KIM C H. Retinoic acid differentially regulates the migration of innate lymphoid cell subsets to the gut [J]. **Immunity**,

- 2015,43(1):107-119. DOI:10.1016/j.immuni.2015.06.009.
- [58] SATOH-TAKAYAMA N, SERAFINI N, VERRIER T, et al. The chemokine receptor CXCR6 controls the functional topography of interleukin-22 producing intestinal innate lymphoid cells [J]. **Immunity**, 2014,41(5):776-788. DOI:10.1016/j.immuni.2014.10.007.
- [59] PEARSON C, THORNTON E E, MCKENZIE B, et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation [J/OL]. **Elife**, 2016,5:e10066. DOI:10.7554/eLife.10066.
- [60] AGACE W W, ROBERTS A I, WU L, et al. Human intestinal lamina propria and intraepithelial lymphocytes express receptors specific for chemokines induced by inflammation [J]. **Eur J Immunol**, 2000,30(3):819-826. DOI:10.1002/1521-4141(200003)30:3<819::aid-immu819>3.0.co;2-y.
- [61] YUAN Y H, TEN HOVE T, THE F O, et al. Chemokine receptor CXCR3 expression in inflammatory bowel disease [J]. **Inflamm Bowel Dis**, 2001,7(4):281-286. DOI:10.1097/00054725-200111000-00001.
- [62] SALLUSTO F, LENIG D, FÖRSTER R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions[J]. **Nature**, 1999,401(6754):708-712. DOI:10.1038/44385.
- [63] TWEEDLE J L, DEEPE GS J R. Tumor necrosis factor alpha antagonism reveals a gut/lung axis that amplifies regulatory T cells in a pulmonary fungal infection[J]. **Infect Immun**, 2018,86(6). DOI:10.1128/IAI.00109-18.
- [64] MAGNUSSON M K, BRYNJÓLFSSON S F, DIGE A, et al. Macrophage and dendritic cell subsets in IBD: ALDH⁺ cells are reduced in colon tissue of patients with ulcerative colitis regardless of inflammation[J]. **Mucosal Immunol**, 2016,9(1):171-182. DOI:10.1038/mi.2015.48.
- [65] DIGE A, MAGNUSSON M K, OHMAN L, et al. Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-alpha treatment in patients with Crohn's disease[J]. **Scand J Gastroenterol**, 2016,51(6):692-699. DOI:10.3109/00365521.2015.1134649.
- [66] 王新月,孙慧怡.基于肺与大肠相表里理论探讨从肺论治溃疡性结肠炎[J].**北京中医药大学学报**, 2011,34(3):153-155.
WANG Xinyue, SUN Huiyi. Treatment of ulcerative colitis from lung based on theory of lung and large intestine being interior-exteriorly related [J]. **Journal of Beijing University of Traditional Chinese Medicine**, 2011,34(3):153-155. (in Chinese)
- [67] 马永利.自拟通腑解毒汤对小儿重症肺炎治疗作用的探讨[J].**中国中医药科技**, 2019,26(5):750-751.
MA Yongli. Study on the therapeutic effect of Tongfu Jiedu Decoction on severe pneumonia in children[J]. **Chinese Journal of Traditional Medical Science and Technology**, 2019,26(5):750-751. (in Chinese)
- [68] 成向进,林朝亮,朱红林,等.应用泻肺通腑法治疗老年重症肺炎患者的临床研究[J].**中国中医急症**, 2018,27(10):1758-1760. DOI:10.3969/j.issn.1004-745X.2018.10.018.
CHENG Xiangjin, LIN Chaoliang, ZHU Honglin, et al. Clinical research of Xiefei Tongfu decoction on patients with severe acute pneumonia[J]. **Journal of Emergency in Traditional Chinese Medicine**, 2018,27(10):1758-1760. DOI:10.3969/j.issn.1004-745X.2018.10.018. (in Chinese)
- [69] 郝红梅,薛西林.薛西林运用“肺与大肠相表里”临证验案3则[J].**江西中医药**, 2018,49(6):28-29.
HAO Hongmei, XUE Xilin. Three empirical cases of “appearance of lung and large intestine” applied by Xue Xilin [J]. **Jiangxi Journal of Traditional Chinese Medicine**, 2018,49(6):28-29. (in Chinese)
- [70] 刘 妙,郑丰杰,高誉珊,等.“从肠论治”对哮喘小鼠 BALF 炎症细胞及血清 IgE 含量的影响[J].**世界中医药**, 2015,10(1):26-29. DOI:10.3969/j.issn.1673-7202.2015.01.006.
LIU Miao, ZHENG Fengjie, GAO Yushan, et al. Effect of relaxing the large intestine on BLIF inflammatory cell and serum IgE in asthma mice [J]. **World Chinese Medicine**, 2015,10(1):26-29. DOI:10.3969/j.issn.1673-7202.2015.01.006. (in Chinese)
- [71] DING Z, ZHONG R, YANG Y, et al. Systems pharmacology reveals the mechanism of activity of Ge-Gen-Qin-Lian decoction against LPS-induced acute lung injury: a novel strategy for exploring active components and effective mechanism of TCM formulae [J]. **Pharmacol Res**, 2020,156:104759. DOI:10.1016/j.phrs.2020.104759.
- [72] ZHU H, LU X, LING L, et al. Houltuynia cordata polysaccharides ameliorate pneumonia severity and intestinal injury in mice with influenza virus infection [J]. **J Ethnopharmacol**, 2018,218:90-99. DOI:10.1016/j.jep.2018.02.016.
- [73] 黄子慧,任丹丹,曹程鸣,等.加味四君子汤对仔猪血清免疫因子水平及肠黏膜免疫的影响[J].**西北农林科技大学学报(自然科学版)**, 2017,45(3):75-81. DOI:10.13207/j.cnki.jnwafu.2017.03.

011.
HUANG Zihui, REN Dandan, CAO Chengming, et al. Effect of supplementary Sijunzi decoction on levels of serum immune factors and intestinal mucosa immunity of piglets[J]. **Journal of Northwest A & F University (Natural Science Edition)**, 2017, 45 (3): 75-81. DOI: 10. 13207/j. cnki. jnwafu. 2017. 03. 011. (in Chinese)
- [74] 金光明, 施恩, 青洁, 等. 中药四黄提取物对肉仔鸡小肠黏膜免疫效果的观察[J]. **中国畜牧兽医**, 2011, 38(1): 65-68.
JIN Guangming, SHI En, QING Jie, et al. The observation of effect in Chinese herbs Sihuang extract on broile small intestines mucosal immune [J]. **China Animal Husbandry & Veterinary Medicine**, 2011, 38(1): 65-68. (in Chinese)
- [75] 单春兰. 黄芪多糖对雏鸡小肠黏膜免疫机能影响的研究[D]. 长春: 吉林农业大学, 2016.
SHAN Chunlan. The study of astragalus polysaccharide on the small intestinal mucosal immunity of chicken [D]. Changchun: Jilin Agricultural University, 2016. (in Chinese)
- [76] 黄鹏. 板蓝根多糖对缺乳仔鼠肠道黏膜免疫功能的影响[D]. 郑州: 河南农业大学, 2012.
HUANG Peng. The mucosal immune function of RIP on the lacking milk renewal rats [D]. Zhengzhou: Henan Agricultural University, 2012. (in Chinese)
- [77] 石玉祥, 闫金坤, 王雪敏. 枸杞多糖对小鼠肠道上皮内淋巴细胞和杯状细胞数量、分布及对 IL-2 水平影响[J]. **食品科学**, 2011, 32 (13): 318-320. DOI: CNKI; SUN; SPKX. 0. 2011-13-070.
SHI Yuxiang, YAN Jinkun, WANG Xuemin. Effect of Chinese wolfberry (Lycium barbarum) polysaccharides on number and distribution of intraepithelial lymphocytes and goblet cells and IL-2 expression in mice [J]. **Food Science**, 2011, 32 (13): 318-320. DOI: CNKI; SUN; SPKX. 0. 2011-13-070. (in Chinese)
- [78] 蒋焱平, 陈刚, 郭彦, 等. 玉屏风多糖对小鼠肠黏膜免疫功能影响的复方效应[J]. **中国兽医学报**, 2018, 38 (9): 1794-1797. DOI: 10. 16303/j. cnki. 1005-4545. 2018. 09. 30.
JIANG Yanping, CHEN Gang, GUO Yan, et al. Compound effects of Yupingfeng polysaccharides on mice intestinal mucosal immune function [J]. **Chinese Journal of Veterinary Science**, 2018, 38 (9): 1794-1797. DOI: 10. 16303/j. cnki. 1005-4545. 2018. 09. 30. (in Chinese)
- [79] 张皖东, 吕诚, 刘振丽, 等. 人参多糖和猪苓多糖对大鼠肠道黏膜淋巴细胞功能的影响[J]. **中草药**, 2007, 38 (2): 221-224. DOI: 10. 3321/j. issn: 0253-2670. 2007. 02. 026.
ZHANG Wandong, LYU Cheng, LIU Zhenli, et al. Effect of ginseng polysaccharide and polyporus umbellatus polysaccharide on function of lymphocytes in enteric mucosa of rats [J]. **Chinese Traditional and Herbal Drugs**, 2007, 38 (2): 221-224. DOI: 10. 3321/j. issn: 0253-2670. 2007. 02. 026. (in Chinese)
- [80] 张磊. 玉屏风散免疫作用机制的研究[D]. 成都: 成都中医药大学, 2006.
ZHANG Lei. Study on the immune mechanism of Yuping Fengsan [D]. Chengdu: Chengdu University of Traditional Chinese Medicine, 2006. (in Chinese)
- [81] 邓桦, 杨鸿, 蒋焱平, 等. 玉屏风多糖影响小鼠淋巴细胞归巢的组织学效应[J]. **中国兽医学报**, 2019, 39 (6): 1170-1174. DOI: 10. 16303/j. cnki. 1005-4545. 2019. 06. 22.
DENG Hua, YANG Hong, JIANG Yanping, et al. Histological effects of Yupingfeng polysaccharide on lymphocyte homing in mice [J]. **Chinese Journal of Veterinary Science**, 2019, 39 (6): 1170-1174. DOI: 10. 16303/j. cnki. 1005-4545. 2019. 06. 22. (in Chinese)
- [82] 吴瑕, 杨薇, 张磊, 等. 不同分子量段黄芪多糖对整体及黏膜免疫功能的影响[J]. **中国实验方剂学杂志**, 2011, 17 (18): 169-172. DOI: 10. 13422/j. cnki. syfjx. 2011. 18. 015. issn: 1005-9903.
WU Xia, YANG Wei, ZHANG Lei, et al. Effect of astragalus polysaccharide segments with different molecular weight on systematic/mucosal immunization in immunodepressive mice [J]. **Chinese Journal of Experimental Traditional Medical Formulae**, 2011, 17 (18): 169-172. DOI: 10. 13422/j. cnki. syfjx. 2011. 18. 015. issn: 1005-9903. (in Chinese)
- [83] 严胜泽. 太子参多糖对环磷酰胺所致免疫损伤小鼠的保护作用研究[D]. 福州: 福建农林大学, 2015.
YAN Shengze. The protective effects of immune injury in mice induced by cyclophosphamide heterophylla polysaccharide [D]. Fuzhou: Fujian Agriculture and Forestry University, 2015. (in Chinese)
- [84] 廖吕燕. “芪苓”制剂多糖对免疫抑制小鼠肠道黏膜免疫及免疫调节作用的影响[D]. 福州: 福建农林大学, 2010.
LIAO Lyuyan. Effect of “QiLing” medicament polysaccharide on intestinal mucosal immunity and immune regulation in immunosuppressed mice [D]. Fuzhou: Fujian Agriculture and Forestry University, 2010. (in Chinese)
- [85] 张琳, 何德根, 陈慧. 自拟中药退热方对 2018 年中山地区甲型流行性感冒患儿呼吸道黏膜免疫功能的影响[J]. **中国中西医结合儿科学**, 2019, 11 (3): 257-259. DOI: 10. 3969/j. issn. 1674-3865.

- 2019.03.022.
- ZHANG Lin, HE Degen, CHEN Hui. Effect of self-prescribed Tuirefang on respiratory mucosal immunity of children infected with influenza A in Zhongshan in 2018 [J]. **Chinese Pediatrics of Integrated Traditional and Western Medicine**, 2019, 11 (3): 257-259. DOI: 10. 3969/j. issn. 1674-3865. 2019. 03.022. (in Chinese)
- [86] 孙正芸,刘海燕. 国内外指南推荐的儿童流感治疗方案[J]. **中华实用儿科临床杂志**, 2017, 32 (18): 1361-1365. DOI: 10. 3760/cma. j. issn. 2095-428X. 2017. 18.001.
- SUN Zhengyun, LIU Haiyan. Domestic and international guidelines recommend treatment regimens for influenza in children [J]. **Chinese Journal of Applied Clinical Pediatrics**, 2017, 32 (18): 1361-1365. DOI: 10. 3760/cma. j. issn. 2095-428X. 2017. 18.001. (in Chinese)
- [87] 雷娜,李艳,何芳雁,等. 解表方通过调节黏膜免疫保护上呼吸道感染模型小鼠的研究[J]. **中国实验方剂学杂志**, 2013, 19 (18): 174-177. DOI: 10. 11653/syjf2013180174.
- LEI Na, LI Yan, HE Fangyan, et al. Study on the protection of upper respiratory tract infection model mice by regulating mucosal immunity with Jiebiao formulation[J]. **Chinese Journal of Experimental Traditional Medical Formulae**, 2013, 19 (18): 174-177. DOI: 10. 11653/syjf2013180174. (in Chinese)
- [88] 刘铁钢,于河,张望,等. 银莱汤对食积复合流感病毒感染小鼠肠黏膜 sIgA、TNF- α 、IL-10 的作用[J]. **北京中医药大学学报**, 2014, 37 (2): 86-89. DOI: 10. 3969/j. issn. 1006-2157. 2014. 02.004.
- LIU Tiegang, YU He, ZHANG Wang, et al. Influences of Yinlai Tang on sIgA, TNF- α and IL-10 in intestinal mucosal tissues of mice with dyspepsia combined with influenza virus infection[J]. **Journal of Beijing University of Traditional Chinese Medicine**, 2014, 37 (2): 86-89. DOI: 10. 3969/j. issn. 1006-2157. 2014. 02.004. (in Chinese)
- [89] 马莉,黄妍,侯衍豹,等. 疏风解毒胶囊免疫调节作用机制研究[J]. **药物评价研究**, 2019, 42 (9): 1763-1768. DOI: 10. 7501/j. issn. 1674-6376. 2019. 09.009.
- MA Li, HUANG Yan, HOU Yanbao, et al. Study on mechanism for immunoregulation of Shufeng Jiedu capsule[J]. **Drug Evaluation Research**, 2019, 42 (9): 1763-1768. DOI: 10. 7501/j. issn. 1674-6376. 2019. 09.009. (in Chinese)
- [90] BAO S, ZOU Y, WANG B, et al. Ginsenoside Rg1 improves lipopolysaccharide-induced acute lung injury by inhibiting inflammatory responses and modulating infiltration of M2 macrophages [J]. **Int Immunopharmacol**, 2015, 28 (1): 429-434. DOI: 10. 1016/j. intimp. 2015. 06.022.
- [91] 孙必强,伍参荣,周英,等. 不同剂型七味白术散对肠道菌群失调小鼠小肠黏膜超微结构和 sIgA 的影响[J]. **中国微生态学杂志**, 2016, 28 (2): 125-128, 137. DOI: 10. 13381/j. cnki. cjm. 201602001.
- SUN Biqiang, WU Canrong, ZHOU Ying, et al. Effects of different formulations of Qiwei Baizhu Powder on the ultrasutstructure of small intestinal mucosa and sIgA in mice with intestinal dysbacteriosis [J]. **Chinese Journal of Microecology**, 2016, 28 (2): 125-128, 137. DOI: 10. 13381/j. cnki. cjm. 201602001. (in Chinese)
- [92] 刘瑶. 藿香正气液对感染后肠易激综合征大鼠肠黏膜屏障保护与调节作用的研究[D]. 广州: 南方医科大学, 2014.
- LIU Yao. Protective and regulative effect of Huoxiang Zhengqi liquid on intestinal mucosal barrier of rats with PI-IBS [D]. Guangzhou: Southern Medical University, 2014. (in Chinese)
- [93] 何颖辉,罗晓健,钱星文,等. 藿香正气胶囊对菌群失调小鼠黏膜免疫的影响[J]. **中国中药杂志**, 2007, 32 (22): 2397-2400. DOI: 10. 3321/j. issn: 1001-5302. 2007. 22.017.
- HE Yinhui, LUO Xiaojian, QIAN Xingwen, et al. Effects of Huoxiang Zhengqi liquid on enteric mucosal immune responses in mice with Bacillus dysenteriae and Salmonella typhimurium induced diarrhea [J]. **China Journal of Chinese Materia Medica**, 2007, 32 (22): 2397-2400. DOI: 10. 3321/j. issn: 1001-5302. 2007. 22.017. (in Chinese)
- [94] 刘冲,段美丽,李昂,等. 内毒素血症大鼠肠黏膜免疫细胞的变化及通腑颗粒的干预作用[J]. **胃肠病学和肝病学杂志**, 2011, 20 (2): 171-174. DOI: 10. 3969/j. issn. 1006-5709. 2011. 02.024.
- LIU Chong, DUAN Meili, LI Ang, et al. Changes of intestinal immune cells and effects of Tongfu granules in rats with endotoxemia [J]. **Chinese Journal of Gastroenterology and Hepatology**, 2011, 20 (2): 171-174. DOI: 10. 3969/j. issn. 1006-5709. 2011. 02.024. (in Chinese)
- [95] 唐秀莹,陈正礼,罗启慧,等. 大豆异黄酮对大鼠肠道上皮内淋巴细胞、杯状细胞及瘦素长型受体的影响[J]. **浙江大学学报(农业与生命科学版)**, 2013, 39 (3): 343-350. DOI: 10. 3785/j. issn. 1008-9209. 2012. 09.301.
- TANG Xiuying, CHEN Zhengli, LUO Qihui, et al. Effects of soybean isoflavones on intestinal epithelial lymphocytes goblet cells and leptin long type receptors in rats [J]. **Journal of Zhejiang University (Agriculture and Life Sciences)**, 2013, 39 (3): 343-350. DOI: 10. 3785/j. issn. 1008-9209.

- 2012.09.301. (in Chinese)
- [96] HUANG G, KHAN I, LI X, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in Apc (Min/+) mice [J]. **Sci Rep**, 2017, 7 (1): 12552. DOI: 10. 1038/s41598-017-12644-5.
- [97] 刘海荣. 大黄多糖与巴豆霜干预 UC 大鼠淋巴细胞归巢作用机制[D]. 天津:天津医科大学,2017.
LIU Hairong. Effects of Rhubarb polysaccharide and defatted croton seed powder on intestinal lymphocyte homing in rats with TNBS-induced colitis [D]. Tianjin; Tianjin Medical University, 2017. (in Chinese)
- [98] GONG J, HU M, HUANG Z, et al. Berberine attenuates intestinal mucosal barrier dysfunction in type 2 diabetic rats[J]. **Front Pharmacol**, 2017, 8: 42. DOI:10. 3389/fphar. 2017. 00042.
- [99] CONG Y, WANG L, KONRAD A, et al. Curcumin induces the tolerogenic dendritic cell that promotes differentiation of intestine-protective regulatory T cells [J]. **Eur J Immunol**, 2009, 39 (11): 3134-3146. DOI:10. 1002/eji. 200939052.
- [100] WANG J, GHOSH S S, GHOSH S. Curcumin improves intestinal barrier function; modulation of intracellular signaling, and organization of tight junctions[J]. **Am J Physiol Cell Physiol**, 2017, 312 (4): C438-C445. DOI: 10. 1152/ajpcell. 00235. 2016.
- [101] SHEN J, CHEN J J, ZHANG B M, et al. Baicalin is curative against rotavirus damp heat diarrhea by tuning colonic mucosal barrier and lung immune function[J]. **Dig Dis Sci**, 2020, 65 (8): 2234-2245. DOI:10. 1007/s10620-019-05977-w.
- [102] 邓海燕,贾立群,潘琳,等. 生姜泻心汤对伊立替康化疗后大鼠肠黏膜免疫屏障的影响[J]. **中国免疫学杂志**, 2007, 23 (7): 620-622. DOI: CNKI;SUN;ZMXZ. 0. 2007-07-014.
DENG Haiyan, JIA Liqun, PAN Lin, et al. Effect of Shengjiangxiexintang on the intestinal mucosal immune barrier of rats receiving Irinotecan [J]. **Chinese Journal of Immunology**, 2007, 23 (7): 620-622. DOI:CNKI;SUN;ZMXZ. 0. 2007-07-014. (in Chinese)
- [103] 于庆生,袁以洋,刘举达,等. 芪黄煎剂对大鼠胃切除后肠黏膜免疫屏障的影响[J]. **中国中西医结合杂志**, 2016, 36 (11): 1358-1363. DOI: 10. 7661/CJIM. 2016. 11. 1358.
YU Qingsheng, YUAN Yiyang, LIU Juda, et al. Effect of Qihuang decoction on the intestinal mucosal immunologic barrier of rats after gastric resection [J]. **Chinese Journal of Integrated Traditional and Western Medicine**, 2016, 36 (11): 1358-1363. DOI:10. 7661/CJIM. 2016. 11. 1358. (in Chinese)
- [104] 周富海,于庆生,张琦,等. 芪黄煎剂对大鼠胃切除后肠淋巴细胞归巢受体 $\alpha 4\beta 7$ 、L-selectin 及 LFA-1 的影响[J]. **中医药导报**, 2016, 22 (2): 12-15. DOI:10. 13862/j. cnki. cn43-1446/r. 2016. 02. 004.
ZHOU Fuhai, YU Qingsheng, ZHANG Qi, et al. Effects of Qihuang decoction on lymphocyte homing receptors of $\alpha 4\beta 7$, L-selectin and LFA-1 after gastric operation in rats [J]. **Guiding Journal of Traditional Chinese Medicine and Pharmacy**, 2016, 22 (2): 12-15. DOI:10. 13862/j. cnki. cn43-1446/r. 2016. 02. 004. (in Chinese)
- [105] 张琦,于庆生,张作军,等. 芪黄煎剂对大鼠胃切除术后免疫相关性肠淋巴细胞归巢数量的影响[J]. **中医临床杂志**, 2016, 28 (3): 415-419. DOI:10. 16448/j. cjtem. 2016. 0154.
ZHANG Qi, YU Qingsheng, ZHANG Zuojun, et al. Effects of Qihuang decoction on the number of immune correlation intestinal lymphocyte homing lymphocytes homing process of gut mucosa after gastrectomy in rats [J]. **Clinical Journal of Traditional Chinese Medicine**, 2016, 28 (3): 415-419. DOI: 10. 16448/j. cjtem. 2016. 0154. (in Chinese)
- [106] 曾兆麟,李玉梅. 从中医肺与大肠相表里理论探索难治性非典型性肺炎(SARS)治疗的新思路[J]. **上海中医药杂志**, 2003, (5): 5. DOI: 10. 16305/j. 1007-1334. 2003. 05. 002.
ZENG Zaolin, LI Yumei. On the treatment of SARS upon Chinese medical theory that lungs pair with large intestine [J]. **Shanghai Journal of Traditional Chinese Medicine**, 2003, (5): 5. DOI: 10. 16305/j. 1007-1334. 2003. 05. 002. (in Chinese)
- [107] LUO E, ZHANG D, LUO H, et al. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China [J]. **Chin Med**, 2020, 15: 34. DOI: 10. 1186/s13020-020-00317-x.
- [108] 郑璐. ICU 内外的中西医合作:专家谈中医药在抗击新冠肺炎中的重要作用[N]. **新华每日电讯**, 2020-03-17(6).
ZHENG Lu. Cooperation of Chinese and Western medicine in ICU: the important role of Chinese medicine in fighting against novel coronavirus pneumonia [N]. **Xinhua Daily Telegraph**, 2020-03-17(6).